AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E.

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE